A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated
Active, not recruiting · NCT05327946 · Registry updated 2026-09-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are Tolerated | Solid Tumors | Active, not recruiting | Phase 1 | 2026-09-01 | NCT05327946 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Boehringer Ingelheim | 158 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Hospitalier de l'Universite de Montreal (CHUM) | Montreal | Canada | 8 |
| Florida Cancer Specialists-Sarasota-61670 | Sarasota | United States | 2 |
| John Theurer Cancer Center | Hackensack | United States | 20 |
| National Cancer Center Hospital | Tokyo, Chuo-ku | Japan | 15 |
| National Cancer Center Hospital East | Chiba, Kashiwa | Japan | 13 |